Exhibit 99.1

Lifeloc Reports Second Quarter 2021 Results

WHEAT RIDGE, Colo., August 6, 2021 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the second quarter ended June 30, 2021.

Second Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $1.730 million resulting in a quarterly net loss of $(110) thousand, or $(0.04) per diluted share. These results compare to net revenue of $1.320 million and quarterly net loss of $(350) thousand, or $(0.14) per diluted share in the second quarter of 2020. Revenue for the quarter increased 31% versus the second quarter last year, as demand recovers from the impact of the COVID-19 global pandemic and the government ordered shutdowns. Net revenue of $3.539 million and a net profit of $294 thousand, or $0.12 per diluted share, compare to net revenue of $3.338 million and a net loss of $(515) thousand, or $(0.21) per diluted share, for the same six months of 2020. The income for the first six months of 2021 includes the benefit from the forgiveness of the first round SBA Paycheck Protection Program (PPP) loan of $465 thousand.

As previously reported, Lifeloc qualified for and received a second PPP loan of $471 thousand in Q1 of 2021. These loans are completely forgivable by the SBA if the proceeds are spent in accordance with the program rules. As with the prior PPP loan, Lifeloc intends to comply with all requirements and plans to apply for forgiveness of this second loan in the third quarter of 2021. The PPP program was successful in mitigating the negative effect of the significant demand suppression on cash flow from the pandemic while allowing Lifeloc to carefully reduce structural costs and retain critical personnel, with no compromise to our product development efforts.

Demand is growing for our new platform LX9 and LT7 devices. The features and performance of the new L-series products have driven penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. We expect that most L-series sales will be incremental to FC-series devices rather than displacing FC sales. The L-series devices are meeting the requirements of the most modern registration standards, such as SAI’s (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors.

We continue to invest in the significant growth opportunities of alcohol monitoring and drug detection. The monitoring opportunity will be addressed primarily through the redesigned Real-Time Alcohol Detection and Reporting (R.A.D.A.R.^®) device. Manufacture of the second generation R.A.D.A.R. 200 prototype devices began in late 2020. Testing of these redesigned R.A.D.A.R. devices and integration with the monitoring system has been extensive and has required additional modification before final release. The design has now been finalized with several devices currently in field testing by key customers and sales release planned this year. Several upgrades have been made to the reporting system including migration to the cloud for higher reliability and an entirely new enrollment app to automate that process.

Our most important goal remains the convergence of the market’s need for rapid detection of drugs of abuse with Lifeloc’s capabilities. Additional personnel and new equipment resources have been committed to finalizing the development of the SpinDx™ technology platform and the rapid, quantitative marijuana breathalyzer built on that platform. We have improved the detection sensitivity for delta-9-THC as well as the robustness of the device. Work continues to develop this system into a device that can be used for roadside testing, as well as other contexts requiring fast response.

“We saw a good uptick in sales this quarter versus last year, although we would still hope to see sales recover more as our customers’ budgets open to replace aging equipment,” commented Dr. Wayne Willkomm, President and CEO. “But our real growth driver is the strong pipeline of recent and upcoming product releases. The L-series platform, a premium product already finding broad acceptance, is providing expanded features requested by various international law enforcement agencies. Together with the imminent release of the redesigned R.A.D.A.R. 200 devices, this should develop a healthy recurring revenue stream to fund growth. The next big milestone for Lifeloc will be completing the commercialization of the SpinDx platform – a major effort that will be prioritized over short-term profitability.”

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc’s stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

R.A.D.A.R.^® is a registered trademark of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans 
Lifeloc Technologies, Inc. 
http://www.lifeloc.com 
(303) 431-9500

 LIFELOC TECHNOLOGIES, INC.

Condensed Balance Sheets

ASSETS
	June 30,
	2021			December 31,
CURRENT ASSETS:	(Unaudited)			2020
Cash	$	2,390,591		$	2,195,070
Accounts receivable, net		499,050			523,603
Inventories, net		2,495,960			2,498,126
Income taxes receivable		275,163			220,657
Prepaid expenses and other		90,766			77,962
Total current assets		5,751,530			5,515,418
PROPERTY AND EQUIPMENT, at cost:
Land		317,932			317,932
Building		1,928,795			1,928,795
Real-time Alcohol Detection And Recognition equipment and software		569,448			569,448
Production equipment, software and space modifications		958,785			958,785
Training courses		432,375			432,375
Office equipment, software and space modifications		216,618			216,618
Sales and marketing equipment and space modifications		226,356			226,356
Research and development equipment, software and space modifications		249,279			190,818
Less accumulated depreciation		(2,405,026	)		(2,277,839	)
Total property and equipment, net		2,494,562			2,563,288
OTHER ASSETS:
Patents, net		138,774			144,702
Deposits and other		163,832			164,798
Deferred taxes		137,494			148,142
Total other assets		440,100			457,642
Total assets	$	8,686,192		$	8,536,348
LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES:
Accounts payable	$	232,015		$	333,851
Term loan payable, current portion		47,910			46,936
Paycheck Protection loan payable		471,347			465,097
Customer deposits		163,425			155,295
Accrued expenses		212,164			266,266
Deferred revenue, current portion		41,998			41,053
Reserve for warranty expense		46,500			46,500
Total current liabilities		1,215,359			1,354,998
TERM LOAN PAYABLE, net of current portion and debt issuance costs		1,253,113			1,277,531
DEFERRED REVENUE, net of current portion		6,162			3,177
Total liabilities		2,474,634			2,635,706
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, no par value; 50,000,000 shares authorized, 2,454,116 shares outstanding		4,650,812			4,633,655
Retained earnings		1,560,746			1,266,987
Total stockholders' equity		6,211,558			5,900,642
Total liabilities and stockholders' equity	$	8,686,192		$	8,536,348

LIFELOC TECHNOLOGIES, INC.

 Condensed Statements of Income (Unaudited)

	Three Months Ended June 30,
	2021			2020
REVENUES:
Product sales	$	1,674,045		$	1,265,698
Royalties		33,652			32,851
Rental income		21,939			21,489
Total		1,729,636			1,320,038
COST OF SALES		1,124,218			991,969
GROSS PROFIT		605,418			328,069
OPERATING EXPENSES:
Research and development		266,633			182,485
Sales and marketing		214,124			274,780
General and administrative		256,908			324,041
Total		737,665			781,306
OPERATING INCOME (LOSS)		(132,247	)		(453,237	)
OTHER INCOME (EXPENSE):
Interest income		813			3,242
Interest expense		(13,544	)		(14,016	)
Total		(12,731	)		(10,774	)
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES		(144,978	)		(464,011	)
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES		35,266			114,419
NET INCOME (LOSS)	$	(109,712	)	$	(349,592	)
NET INCOME (LOSS) PER SHARE, BASIC	$	(0.04	)	$	(0.14	)
NET INCOME (LOSS) PER SHARE, DILUTED	$	(0.04	)	$	(0.14	)
WEIGHTED AVERAGE SHARES, BASIC		2,454,116			2,454,116
WEIGHTED AVERAGE SHARES, DILUTED		2,454,116			2,476,222

 LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Income (Unaudited)

	Six Months Ended June 30,
REVENUES:	2021			2020
Product sales	$	3,449,492		$	3,203,564
Royalties		46,216			92,132
Rental income		43,471			42,678
Total		3,539,179			3,338,374
COST OF SALES		2,109,884			2,232,229
GROSS PROFIT		1,429,295			1,106,145
OPERATING EXPENSES:
Research and development		573,845			479,382
Sales and marketing		444,602			601,344
General and administrative		607,028			680,928
Total		1,625,475			1,761,654
OPERATING INCOME (LOSS)		(196,180	)		(655,509	)
OTHER INCOME (EXPENSE):
Forgiveness of Paycheck Protection loan		465,097			—
Interest income		1,312			10,418
Interest expense		(27,061	)		(28,147	)
Total		439,348			(17,729	)
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES		243,168			(673,238	)
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES		50,591			158,340
NET INCOME (LOSS)	$	293,759		$	(514,898	)
NET INCOME (LOSS) PER SHARE, BASIC	$	0.12		$	(0.21	)
NET INCOME (LOSS) PER SHARE, DILUTED	$	0.12		$	(0.21	)
WEIGHTED AVERAGE SHARES, BASIC		2,454,116			2,454,116
WEIGHTED AVERAGE SHARES, DILUTED		2,454,116			2,454,116

 Lifeloc Technologies, Inc.

 Statements of Stockholders' Equity (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021		2020
Total stockholders' equity, beginning balances	$	6,321,270		$	6,659,026		$	5,900,642	$	6,792,221
Common stock (no shares issued during periods):
Beginning balances		4,650,812			4,635,415			4,633,655		4,603,304
Stock based compensation expense related
to stock options		—			312			17,157		32,423
Ending balances		4,650,812			4,635,727			4,650,812		4,635,727
Retained earnings:
Beginning balances		1,670,458			2,023,611			1,266,987		2,188,917
Net income (loss)		(109,712	)		(349,592	)		293,759		(514,898	)
Ending balances		1,560,746			1,674,019			1,560,746		1,674,019
Net income (loss)		(109,712	)		(349,592	)		293,759		(514,898	)
Stock based compensation expense related to stock options		—			312			17,157		32,423
Total stockholders' equity, ending balances	$	6,211,558		$	6,309,746		$	6,211,558	$	6,309,746

LIFELOC TECHNOLOGIES, INC.

 Condensed Statements of Cash Flows (Unaudited)

	Six Months Ended June 30,
	2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	293,759		$	(514,898	)
Adjustments to reconcile net income (loss) to net cash provided from (used in) operating activities-
Forgiveness of Paycheck Protection loan (round 1)		(465,097	)
Depreciation and amortization		133,657			191,493
Provision for doubtful accounts, net change		(49,000	)		5,000
Provision for inventory obsolescence, net change		(5,000	)		42,265
Deferred taxes, net change		10,648			(11,516	)
Stock based compensation expense related to stock options		17,157			32,423
Changes in operating assets and liabilities-
Accounts receivable		73,553			96,567
Inventories		7,166			(486,414	)
Income taxes receivable		(54,506	)		(146,807	)
Prepaid expenses and other		(12,804	)		(88,920	)
Deposits and other		966			(58,823	)
Accounts payable		(101,836	)		96,684
Customer deposits		8,130			(47,951	)
Accrued expenses		(54,102	)		(79,974	)
Deferred revenue		3,930			(4,365	)
Net cash provided from (used in) operating activities		(193,379	)		(975,236	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(58,461	)		(9,088	)
Patent filing expense		—			(18,772	)
Net cash provided from (used in) investing activities		(58,461	)		(27,860	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments made on term loan		(23,986	)		(22,899	)
Proceeds from Paycheck Protection loan (round 2)		471,347			465,097
Net cash (used in) financing activities		447,361			442,198
NET INCREASE (DECREASE) IN CASH		195,521			(560,898	)
CASH, BEGINNING OF PERIOD		2,195,070			3,185,996
CASH, END OF PERIOD	$	2,390,591		$	2,625,098
SUPPLEMENTAL INFORMATION:
Cash paid for interest	$	—		$	27,605
Cash paid for (received from)  income tax	$	—		$	20,063